Publications

Publications

Metastasis as a therapeutic target in prostate cancer: a conceptual framework

By:
Contributors: Andries Zijlstra Research Group, Katie Hebron, John D. Lewis Research Group, David Bond, PhD, Konstantin Stoletov, PhD, Srijan Raha
Am J Clin Exp Urol. 2014 Apr;2(1):45-56.

Abstract

Metastasis is the main cause of prostate cancer-associated deaths. While significant progerss has been made in the treatment of primary tumors, efficent therapies that target the metastatic spread of prostate cancer are far from clinical reality. To efficiently treat cancer we need be able to impede its spread. Unfortunately, the majority of current therapeutics approved to treat metastatic cancer were originally selected based on their ability to inhibit primary tumor growth. This inherent flaw precluded these therapies from efficiently targeting the development of secondary metastatic lesions, a process that is distinct from that of primary tumor progression. In this review we will summarize the conceptual, cellular and molecular targets that should be considered to design effective anti-metastatic therapies.

 

PubMed

Download PDF

 

Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients

March 11, 2022

Congratulations to authors and APCaRI members Sunil Rajput, PhDDesmond Pink, Scott Findlay, Emma WoolnerJohn Lewis, and Mark McDermott on their recent publication in ACS Sensors! The authors demonstrate a novel assay that detects and quantifies a specific protein biomarker in serum from advanced prostate cancer patients, leading to better-informed prostate cancer treatment.
Article

- Unknown